The global high potency API contract manufacturing market, valued at USD 8 billion in 2022, is poised for robust growth, with projections to reach USD 16 billion by 2032. This remarkable expansion, ...

The subcutaneous version still needs to be administered ... with natalizumab and a high-concentration formulation of AbbVie's immunology drug Humira (adalimumab) highlighted as those with the ...

Tepkinly is given in hospital as a once-weekly subcutaneous injection for 12 weeks ... competition to its immunology blockbuster Humira (adalimumab).

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

In a lawsuit filed Thursday in a New Jersey federal court, Halozyme alleges that a proposed subcutaneous formulation of Merck’s popular cancer drug Keytruda infringes 15 of its patents.

Survey results revealed a widespread – and often misguided – belief that subcutaneous delivery volumes must be limited to 3 mL or less without a permeation enhancer (an enzyme co-formulated ...